US appeals court allows continued sale of generic Omnicef
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has failed in its bid to have a federal appeals court rule that generics of the cephalosporin antibiotic Omnicef (cefdinir) infringe its patent. The May 18th en banc decision from the US Court of Appeals for the Federal Circuit allows a generic cefdinir product to remain on the US market.